First-in-human, placebo-controlled, single- and multiple-ascending dose study of GS 4997 in healthy subjects.

Trial Profile

First-in-human, placebo-controlled, single- and multiple-ascending dose study of GS 4997 in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Selonsertib (Primary)
  • Indications Diabetic nephropathies; Non-alcoholic steatohepatitis; Pulmonary arterial hypertension
  • Focus Adverse reactions; First in man
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top